The market cap right now post dilution is what 700M?. We now have enough capital to get through trials and through approval if needed using the line of credit. Pharmasett was purchased this past year (by Gilead I think) for $11B for a drug with similar therapeudic potential as Afrezza, in a much smaller market (Hep B and C), and further behind in testing. Let's assume MNKD has the same potential (it's larger but play with me here) that would yield well over $20 to me and that takes into account nothing additional for technosphere platform (which I think is the long term secret weapon).

I think you are just plain wrong.